D3 Bio Gets FDA Clearance for Two IND Trials in KRAS Cancers
D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared...